-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 IYBZpWf9hi0qIc8hWuzscXOpQxED5+3T2LniuV6mfgvSUilGsdSnuVouEKZzlfwP
 h6RWDEwprXWzMdOdEQgMSg==

<SEC-DOCUMENT>0000950123-10-022310.txt : 20100309
<SEC-HEADER>0000950123-10-022310.hdr.sgml : 20100309
<ACCEPTANCE-DATETIME>20100309070551
ACCESSION NUMBER:		0000950123-10-022310
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100303
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100309
DATE AS OF CHANGE:		20100309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OMEROS CORP
		CENTRAL INDEX KEY:			0001285819
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34475
		FILM NUMBER:		10665257

	BUSINESS ADDRESS:	
		STREET 1:		1420 5TH AVE
		STREET 2:		SUITE 2600
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
		BUSINESS PHONE:		206-623-4688
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v55176e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, DC 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Date of Report (Date of earliest event reported): March&nbsp;3, 2010</B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>OMEROS CORPORATION</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Washington</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>001-34475</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>91-1663741</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction of <BR>
incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer<BR>
Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>1420 Fifth Avenue, Suite&nbsp;2600<BR>
Seattle, Washington 98101</B><BR>
(Address of principal executive offices, including zip code)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(206)&nbsp;676-5000</B><BR>
(Registrant&#146;s telephone number, including area code)<BR>
(Former name or former address, if changed since last report)</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>












<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<!-- link1 "Item&nbsp;1.01 Entry into a Material Definitive Agreement" -->
<DIV align="left"><A NAME="000"></A></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Item&nbsp;1.01 Entry into a Material Definitive Agreement.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;3, 2010, Omeros Corporation (&#147;Omeros&#148;) and Asubio Pharma Co., LTD. (&#147;Asubio&#148;) entered
into a License Agreement (the &#147;Agreement&#148;) pursuant to which Omeros received an exclusive license
to phosphodiesterase-7 (&#147;PDE7&#148;) inhibitors claimed in certain patents and pending patent
applications owned by Asubio for use in the treatment of movement disorders and other specified
indications. Omeros intends to use these inhibitors in its PDE7 program, which is based on Omeros&#146;
demonstration of a previously unknown link between PDE7 and any movement disorders, such as
Parkinson&#146;s disease and Restless Legs Syndrome.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Agreement, Omeros has agreed to make development and sales milestone payments to
Asubio of up to $23.5&nbsp;million upon the achievement of certain events, such as successful completion
of preclinical toxicology studies; dosing of human subjects in Phase 1, 2 and 3 clinical trials;
receipt of marketing approval of a PDE7 inhibitor product; and reaching specified sales milestones.
In addition, Asubio is entitled to receive from Omeros a low single-digit percentage royalty of
any net sales of a PDE7 inhibitor licensed under the Agreement by Omeros and/or its sublicensee(s),
provided that if the sales are made by an Omeros sublicensee, then the amount payable by Omeros to
Asubio is capped at an amount equal to a low double-digit percentage of all royalty and specified
milestone payments received by Omeros from the sublicensee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The term of the Agreement continues so long as there is a valid, subsisting and enforceable
claim in any patents covered by the Agreement. The Agreement may be terminated sooner by Omeros,
with or without cause, upon 90&nbsp;days advance written notice or by either party following a material
breach of the Agreement by the other party that has not been cured within 90&nbsp;days or immediately if
the other party is insolvent or bankrupt. Asubio also has the right to terminate the Agreement if
Omeros and its sublicensee(s) cease to conduct all research, development and/or commercialization
activities for a PDE7 inhibitor covered by the Agreement for a period of six consecutive months, in
which case all rights held by Omeros under Asubio&#146;s patents will revert to Asubio.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the pending business reorganization of Asubio, Omeros has been informed by
the parent company of Asubio, Daiichi-Sankyo, Company, Limited, that it intends to succeed to all
of Asubio&#146;s rights and obligations under the License Agreement on April&nbsp;1, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The foregoing description of the Agreement is only a summary of its material terms and does
not purport to be complete.
</DIV>
<!-- link1 "Item&nbsp;9.01 Financial Statements and Exhibits" -->
<DIV align="left"><A NAME="001"></A></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits.</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="92%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release dated March&nbsp;9, 2010 announcing License
Agreement between Omeros Corporation and Asubio Pharma Co.,
Ltd.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- link1 "SIGNATURES" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>OMEROS CORPORATION</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Gregory A. Demopulos
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Gregory A. Demopulos, M.D.&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">President, Chief Executive Officer,
Chief Medical Officer and Chairman
of the Board of Directors&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Date: March&nbsp;9, 2010
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- link1 " EXHIBIT INDEX" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT INDEX</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="92%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release dated March&nbsp;9, 2010 announcing
License Agreement between Omeros Corporation
and Asubio Pharma Co., Ltd.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v55176exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 18pt"><b>Exhibit 99.1</b>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><IMG src="v55176v5517600.gif" alt="(OMEROS LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Omeros Licenses PDE7 Compounds for Parkinson&#146;s Disease Program</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Seattle, Washington &#151; March&nbsp;9, 2010 &#151; </B>Omeros Corporation (Nasdaq: OMER) today announced that
it has obtained an exclusive license to compounds from Asubio Pharma Co., Ltd. for use in its PDE7
program, which is focused on the treatment of movement disorders. Omeros has demonstrated a
previously unknown link between phosphodiesterase-7 (PDE7) and movement disorders such as
Parkinson&#146;s disease and Restless Legs Syndrome. The agreement with Asubio gives Omeros an expedited
path to the clinic by providing advanced preclinical product candidates that are ready for
additional toxicology studies in preparation for a Phase 1 clinical trial.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;We are pleased to have accessed these PDE7 inhibitors. Omeros has already conducted
successful preclinical studies with them, and has identified which in-licensed candidate we plan to
move forward into clinical trials,&#148; stated Gregory Demopulos, M.D., chairman and chief executive
officer of Omeros. &#147;We expect that our first clinical program will target Parkinson&#146;s disease and,
assuming continued preclinical progress, that we will be able to file an investigational new drug
(IND)&nbsp;application to begin a Phase 1 clinical trial in 2011.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Under the agreement, Omeros is responsible for clinical and commercial milestone payments to
Asubio. Omeros would also pay a single-digit royalty to Asubio upon potential sale of the products
named in the agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Omeros&#146; PDE7 Program</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Omeros&#146; PDE7 program is based on a previously unknown link between PDE7 and any movement
disorder such as Parkinson&#146;s disease and Restless Legs Syndrome. Based on promising preclinical
animal data in a model of Parkinson&#146;s disease showing efficacy of PDE7 inhibitors equivalent to
that of levodopamine, the Company is advancing proprietary compounds for the treatment of movement
disorders. Levodopamine has been the standard treatment for Parkinson&#146;s disease for nearly 40&nbsp;years
but is associated with severe side effects including dyskinesias, hallucinations, sleep disorders
and cognitive impairment. Omeros&#146; PDE7 inhibitors may have the ability to avoid one or more of
these side effects. The Michael J. Fox Foundation has been a supporter of this program, having
provided grant funding of $464,000 to Omeros to date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Parkinson&#146;s Disease</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Parkinson&#146;s disease is a progressive, degenerative disorder of the central nervous system that
can impair a person&#146;s motor skills, speech and other functions. The disease is characterized by
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">tremors, muscle rigidity and the slowing of physical movement. It is chronic and progressive and
affects approximately one million people in the United States. There is currently no cure for
Parkinson&#146;s disease.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Asubio Pharma Co., LTD.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Asubio Pharma is a research oriented biopharmaceutical company and a wholly owned subsidiary
of Daiichi Sankyo Co., Ltd., headquartered in Japan. Asubio focuses on research and development of
innovative ethical drugs in the field of inflammation, regeneration and differentiation. Asubio has
cutting-edge technologies for innovating first-in-class small molecule medicines, peptide medicines
and stem cell-derived medicines for tissue regeneration.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Omeros Corporation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and
commercializing products focused on inflammation and disorders of the central nervous system. The
Company&#146;s most clinically advanced product candidates are derived from its proprietary
PharmacoSurgery&#153; platform designed to improve clinical outcomes of patients undergoing a wide range
of surgical and medical procedures. Omeros has five ongoing clinical development programs,
including four from its PharmacoSurgery&#153; platform and one from its Addiction program, the most
advanced of which is in Phase 3 clinical trials. Omeros may also have the near-term capability,
through
its GPCR program, to add an unprecedented number of wholly new drug targets to the market.
Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of antibody
and small-molecule preclinical programs targeting inflammation and central nervous system
disorders.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Forward-Looking Statements</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This press release contains forward-looking statements as defined within the Private Securities
Litigation Reform Act of 1995, which are subject to the &#147;safe harbor&#148; created by those sections.
These statements include, but are not limited to, statements regarding the Company&#146;s ability to
file an IND in 2011 and to begin a Phase 1 clinical trial for Parkinson&#146;s disease. Forward-looking
statements are based on management&#146;s beliefs and assumptions and on information available to
management only as of the date of this press release. Omeros&#146; actual results could differ
materially from those anticipated in these forward-looking statements for many reasons, including,
without limitation, the risks, uncertainties and other factors described under the heading &#147;Risk
Factors&#148; in the Company&#146;s Quarterly Report on Form 10-Q filed with the Securities and Exchange
Commission on November&nbsp;19, 2009. Given these risks, uncertainties and other factors, you should not
place undue reliance on these forward-looking statements, and the Company assumes no obligation to
update these forward-looking statements publicly, even if new information becomes available in the
future.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Contact:</U><BR>
Jennifer Cook Williams<BR>
Cook Williams Communications, Inc.<BR>
360-668-3701<BR>
jennifer@cwcomm.org

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt"># # #
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>v55176v5517600.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v55176v5517600.gif
M1TE&.#EAB`!<`.8``'B2I.2)%>/IZVN&G.Z[:3=5>?7:J.."'_GGQX*9JOWZ
M\MKCY.JH0YJMNN>6)O+V]O##=_KMT^SQ\O'(@B1#;>VT6:F\Q/CZ^N>6->2$
M"UQWD?CCO++#RO34G/STX]]I`N!S`\/0U0\N7BI)<1(R8>JF5;W*T9NPN^%\
M`_[\^-3=X:"UOO[^_OS\_.!U"TQCA?;X^,G5V>^\>45@@H^HLO;>LF%]E,'-
MU*2UP>)\%?SVZ>B@-*6YPLS8W.B<0O+-D!HZ9OOPV^)]"E%HB%9RCN?M[HB?
MKI2LMM';WS%.=/[^_+K)S[2^RI&CM=?@X^:/&L;3U]]N`D]MBAT]:#U:??/V
M]M]M`B(^:>:.+_WX[>#FZ96JN+C%SO3X]T)>@*[`Q]WEY^!P!:FVP^KN\.RP
M9/K[^_7W]]]L!;7'S$QGAM_HZ:Z]Q^NO3Q8U8^_R\_#T]#%2=D9FA?W^_O[]
M_OW^_?W]_=]K`O[]^Y^POA@X9?OZ^\#/TYFIN.KP\`PK7/___R'Y!```````
M+`````"(`%P```?_@'^"@X2%AH>(B8E*.HJ.CY"1DI.4E8A9/RF6FYR=GI^$
M!E@&H*6FIZ85+@RHK:ZOB@@'9P=!L+>XJ!5A'V$0N<#!E@@Y'\8''L+*RXF[
MQKT=S-+2$0?/O033VL%W$"[7+A,1V^2P01AVSV<.;`2:Y?"E2AW%SSD=3UCC
M\?R='B51GH5AT\'*@0DL^BFL],/:!Q!A#AAP\"&*CV0+,S[*4H(7"!`N*DRP
M8BP'A(0:4QX290P%B%$,GEG$^(>%@BPI4*KLIX#,MS`HA$"($/.9Q!0Z(M3X
M(>[.3H4;L+0$X6"#@@X!C;DH\8.`CP!`#;Q["N^.C&^]4$#(PL(#18$N_T@:
M`_$C"]EX$7RD^V#'`0*G*7YDO7:-`,V[VE+0>P:"@-T_=Q"@(/S,3AC#B,EY
M(&/%2KJJFNY$(##YFI4H+K`P,*`@\[8:6$!D^%B!K9(@;`*`("S$`8,?&R`0
MZ!!AK.M@'@B$`>'RB=@_'BKHWOM,"`$$.CSX<'$`RXX.CX_G8AD%A)`*01)V
MT$WYH0P%+'2@,Q;E0(5]XF%ED1$F2@8A3_S0F@<[9'!&9=?XL,$?\AWXC`L^
M1)/?*PCX\!`**+"QSP0!E':A7.XAA4%[!R`P82LL&!#`0QDXT$%K$3@`0E8O
M0?"6,1@$D04#'EY3PF$G?J(`AR`\L4,%""1DP/\34831&0@5>"`#B$(DJ4`0
M!O!XS0$_!%E*6PR8U^*+-;$A1`88HO!$!"QLL.(SAK'`PAU($>#0!S[@YR4G
MD>D60``,L/E'"CN@T&%0!"CQ1Q`E4!?`!DX)TE9#Q_R@TYZ69#%!%`$\D<%:
M@F3QA)K,/2K('1V@98P,0%Y5C`L$1(II)2Q$@$&1G1J`D@ZC.G"F`S0A(-4S
M?ET*'0$5D6'<K))@$E0`&3@VB`X.H.!`!@'L,%9/O!@3AH"%W+&!"U$HRVPE
M$>S@7P`EZ)D"`[U!RTHHP^)H8B%!Q&;NN9*D4(,0862`12:$*`%!!CM4RX"B
M@TB)Q<-88%"#L=J99"S_OXHD9X5L9-A2R`\!..`K`\LJ9<#)!J17B':C8"R)
MBE$(P<"]A2"0\`Y/L!&>)$$X0$8C+D-2P:\U+"N(`A`PH#0!'O=;@X)!0Z+`
M$X`2H,/%@FQ`@-+W4:(#!!.T%K4C^+"1,M:"I#`!&VS,/(D"-4P`Y-B&O'L0
M?(Y$`$$%(AEM2`<$$,"&`WP''GCA@1N`0!:R\EM#`&RH[$@*$;`-`<V),.""
M"_UM[OGG+CCP`W9^8TK`$S4TG@@+*6Q0`1OBY)0(`0ZV]Q"@$RA^M<M*[!`V
MUG(6PGH$/U1`0`V,!U\(!+4_8P4*+AC*P`0U;*"#ZLPB0'(B*2C@_??@(R`<
M_W`ZJDX[85%8*U(-07@@>]3`H7W'#PYT^L3]^-_O`-5HWG<I&\W[@`NR10#J
M!0%O46L=]@BA`P((P7:4:5<A)@`P%_Q'"!A\0@4,`#2ZO0P+`6R/!%<6`?=U
M+P4H1)L'R09""!ICA"N$!6RZ93L8QO`53SN`#G?(PX[=$!<>0,`&ADA$(A;G
MATA,HA*7R,0F.O&)4(RB%*?8CQ8LP`D/0$0=^K"$%>P!#4>`0A83L44D.*$*
MBIA#%<``!C6\01%RZ`,'C````-``"F\LQ`78J(8^+F`!8'!#"R11!##N@0<G
M"($;",F!!`S``H1P0AT38`,+U($0=7!"`@IPA0(X\O\*5X@##L9P24,\``^@
MU$`(!GF((@``E`5H`"):(``C)&$*5Z"`+BF0!BZ44A`"H``H*3""$>@2#C:X
M017D@`@67,`)MLRE$88`2B]PX`TJW",`D@#*$=B@"X)8``V,D``:6,`(*AB$
M')Q`!""0(`D)@,(:I-`&$HP@`46XV`/X(`(_D&``:C@$"Y!0`#_X801;0(03
M!@`$$4S!!@T0PQ8TD`0C7(`016B#02F0``!0H0TB:(,7+)!'0US@!AIP9P$`
M`(45I"$/(J"`$;!YB#(L00-3L"<`.""`4H8``&L`P`#XP(,02$H`5#!H$F(P
M"`$0H9\D,$(5C+7/?OHA"3S_^.4@JH`#JXY`EH:H@@9(X(<VT*`0,8C!10>1
M43^(8`8)40,`-.H'.'#A8G6X@1<,F@:C"N(!-J"K$<Q@K#J$H*!^*``2M/J'
M&P!`#",@PA*6P`%!N"$.&UU!(;@`!X-.`0JL'$15#2H"`/3!$&`@@D$/"E9"
MM```>7"K%-:JB#YH]*UK7<``2)N`,0Z"!450K1\H4%E"]""I_EQ":`51!!OT
MDP(A*(,A?KH&'-``#UM@*AUH8-`VV$!U+1A`;/U@@WP28K0&C8-?"6&"*:QV
M!"<P1`RNX-D>0*(+L<7M("S@7C]XP0F%*(,8^BD"(IC!$$:P*A$DL-D1&!0`
M:#1$_Q%6$$\D\,`(`OB#&BBP44@:`@V(S0,':/L']!X4!\8"@%6OJEE"E,$&
M9!6!%"*!7[?.@+8F2,)&0Z"3.H"ALWZX@A$.T0.K4L##@FA!`S1*@C4P=A`2
M""H`MK``033`JG!()VJ'L%H;C.&\_%PM"1)`XC_$8<5):/$@P.!@?P*`QOF]
M\2"@@%@@F$`G%SC!:I-0W$*\H;_>E:X@JI!@?S+AR8F`@096FX8OAQ7&!AV!
M"ICY5WZ*P*H:*`(AJC`"$9"5Q87@P7C;@&1'=`$(-J8MG3U[YT&X0;A^F$&5
M#X%9@Q8`#(-X0P((W(`R*\()R/7#``Y\B`3T5P1<H&U5I__0WR0@@=)_,`$)
MI@#D-!<"`)\&@I8?T07WZE<0(:AV#%#"`@&TF00:@`$B`+#:(P\"!DW`M'DA
M@08=&]2BB&A`F_W0`-]6M0!I@"H>?*N!/,1AT5?%`28U8.22.N("'/[V'SC`
M8?)F.,DAL"H0`("V%6@\`8.H@Q@`30.'*^($%??#"GPM"`L`V0]&6&2EWPJ`
MB@]`"\#4I1%V6]=2FV$&!"Z`H!\!\50+`@9;T.@4>CV("ZR@W4-&!!JLFH<!
M$.*P>UZ#NA]A[-5^8>B%`/%J`>#H$O/S!5^8@4&I@`1!\$`$5`@!SPM0ZCX@
M%^X,(WK$Y5R'&$C!K1K8]A^JD(#_]\87$5"P:ALTD/<Q#("N_EW"UA4!`%0;
M5+F(,$&P!Z#IF;]@H?T$`A>DN]L!+,`&MBXU&.PM@C@L@`>PAST.\&`!7!.B
MZ&^%P1MN8`,@Y$$*DB?$&WA^4!XDHL@&)8$4],!>Q!IT"%]XA'A7N\K,!]L&
M%S>["%XPABW87``P</`7P(#ZQ)9:!?96_A&8S?XI`('N>MS[&(PP@FD;00ME
M'OZ>HX\(Y/MS",S7=%\0;"(P`GV&"--G4#&`:'\@=@;%>:)U=G*$7'#0`TA`
M`B3@!%I0?O`W"$Z0?G$`!0DP@B0(`$9@7[>W=P_0`-TU6(:@?P8%!P=8"(F7
M?$00@**U_P;[)@(%L`249WE^``4,Z')C5W95]0)]0'[)9UTBX`55(``<6&H+
MP'HS``-%<(58*`!%,'F"@'LWU@,5EP9MYV?L%H,S2`A3UUT:\&0/@`/T15I>
MP&"(8`0I9P++10A'L&\Q%X';UP=RX'T&90,#(`(\0$M12`@2<'<%P'*'X(47
M\`"#Z$]\P(5_8`;<%6EJ9@@G0'56=P@M8`(I1P)'D`@KL&]?APA=9U`#QX=(
M^`<A4&L%<`04(`'E5G[6UG0O8&3@!`F.R`(X4'$V,&M-9P'M-HKKMEI3`'):
MQ%^D-6.(L`3VY@='P')E,`"?)@(F,'1'>%IJ4'YML`4G,$A0J/]4F<@"D.8'
M4V![>F=T/2!<%+`&RU4'*O!IR9@(4F!D_(<(94`$GY8$B:`&>_6`Q%8(`L!E
MMJ8%.K&-?U`&1O!I&C!5?S".H$8(1D!7;9"/IH9J^G4!>`",`/9;8P!DZ$:)
M@F`&%=>$IZ4(6]!LB7`!Y><'C78(4!"0(C!38"8":7!:+$!Q,4AL$GF+@V`"
M;SAF<&9T+*`""#<"AR9\+^D%ZD@("T"/"<"`^_6&_I@(/-"/3%4(<J!OD:8"
M6E550R"'18!<5."3MIB)?P`#7D!@4G"'B%!CWU8&?'!;`.!P%_`%GS8"I38(
M7V!5BO4(;NA61*`(;F!O%'`$QB(!8^7_5C9YDV,Y"-,'`((FD?!E""O07Q00
M4(]@!G%&6S=@;W`P;H1P60:U<8QU`<0'`"1I"+#E3X>'E:A&`K+F8GC@8'"W
M`'10"&(IAW_``R,@>BAAF:WE:D-`5O\TD()0!RUP*6[PF8,P!LYE4`F@G"W`
M!?WU7]!6!U]@;TG@!%0I"$Y0`)=&!66'"!<``.[E76"0$!<0`[GH!U0P>J;$
M3Y$93@5`!2@8D>7W58>@`FE`5GG0`'G$`A)@`CU`8FW5A"2&`VU6``@I?.I9
M5@``GG]P`:](5G"P!^&)H5)``MNWE8[P!C7G!U7'`2:``QK0!FU`!3B@G*SH
MFQ>@`0`U"%J`_W`4D%"'P`5#H%$CT`1+<`-<8`1QT`0*^FD%P(5@,`10]:*%
MH%L<1@$#L`9+@`=I4$\C!9>",`=CT`,X$`<D0`%#``62H&M4X$XC4``4T`;>
MQ`6^Q9NWJ0&^^0<X8`*^)0`#H$M4$)MZ!`4#D`0DT`9P0`5P0`%4(`9:503%
M-`)IP(4MD`"%2@$:(`"74@=:8`1>``1L"@=3P*8:$`.[.4MKH`%7``14D`#[
M&0EFL`<)(`4S,`,O8`-B4`14^4PXL`0D]@8P`&U5<`,G<`(\('C"\P!?,``O
M\*I#D``A8'(/L`+.R@%WZ`06\*LK0*N&``,QD`!$\*II,``\D'V)8$P!4O`"
M`!`"C.@(<O``8*`"2+``10!VJS,'CL`"+5"O+2"OBF"@"X`$2``&$&D(=1"P
=B":P`=M,#Z`&3M"N8P"OB/``*N`$;P!MCA`(`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
